Yutaka Shiraishi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yutaka Shiraishi has a total of 37 co-authors. Here are the top co-authors by number of shared publications:
Kazuhito Toya
3 shared publications- Atsunori Yorozu
Department of Radiation Oncology, National Hospital Organization Tokyo Medical Center, Tokyo, Japan
2 shared publications Naoyuki Shigematsu
Department of Radiology, Keio University School of Medicine, Tokyo, Japan
2 shared publications- Naoyuki Shigematsu
Department of Radiology, Keio University School of Medicine, Tokyo, Japan
2 shared publications - Shiro Saito
National Hospital Organization Tokyo Medical Center
2 shared publications Toshio Ohashi
Department of Radiology, Keio University School of Medicine, Tokyo, Japan
2 shared publications
Latest Publications
- Open Access
- 26 November 2025
- Published by Springer Nature in Research Square
Radiomics modeling to predict the tumor immune-microenvironment of mucinous adenocarcinoma of gastric-type cervical cancer
Gastric-type adenocarcinoma (GAS) of the cervix is usually diagnosed at advanced stages and has a poor prognosis due to resistance to standard therapies. Although immune checkpoint inhibitors have improved outcomes in cervical cancer, prognosis and treatment response are strongly influenced by the tumor immune microenvironment (TME). Histopathological assessment of GAS is challenging because it often arises in the upper cervix. This study aimed to predict the TME in GAS using MRI-based radiomics. We enrolled 16 patients with GAS treated at our institution. Tumor-infiltrating lymphocytes (TILs) were evaluated by immunohistochemistry, quantifying them with the Immunoscore. Fourteen patients with usual endocervical adenocarcinoma (UEA) served as controls. A total of 1,309 radiomic features were extracted from the primary tumor and peritumoral region on pre-treatment MRI images. After feature selection, clustering, and regression models were developed to predict the TME in GAS. GAS exhibited significantly lower T-cell infiltration than UEA, particularly in early-stage tumors. The clustering model achieved 87.5% accuracy in Immunoscore classification, and the regression model showed a strong correlation with observed TIL densities (r = 0.93, P < .001). These findings suggest that MRI-based radiomics may serve as a noninvasive biomarker for predicting the TME in GAS.
- 26 November 2025
- Published by Springer Nature in Research Square
Open AccessRadiomics modeling to predict the tumor immune-microenvironment of mucinous adenocarcinoma of gastric-type cervical cancer
Gastric-type adenocarcinoma (GAS) of the cervix is usually diagnosed at advanced stages and has a poor prognosis due to resistance to standard therapies. Although immune checkpoint inhibitors have improved outcomes in cervical cancer, prognosis and treatment response are strongly influenced by the tumor immune microenvironment (TME). Histopathological assessment of GAS is challenging because it often arises in the upper cervix. This study aimed to predict the TME in GAS using MRI-based radiomics. We enrolled 16 patients with GAS treated at our institution. Tumor-infiltrating lymphocytes (TILs) were evaluated by immunohistochemistry, quantifying them with the Immunoscore. Fourteen patients with usual endocervical adenocarcinoma (UEA) served as controls. A total of 1,309 radiomic features were extracted from the primary tumor and peritumoral region on pre-treatment MRI images. After feature selection, clustering, and regression models were developed to predict the TME in GAS. GAS exhibited significantly lower T-cell infiltration than UEA, particularly in early-stage tumors. The clustering model achieved 87.5% accuracy in Immunoscore classification, and the regression model showed a strong correlation with observed TIL densities (r = 0.93, P < .001). These findings suggest that MRI-based radiomics may serve as a noninvasive biomarker for predicting the TME in GAS.
- 1 November 2016
- Published by Elsevier in Brachytherapy
- Vol. 15 (6) , 768-773
Single-energy metal artifact reduction in postimplant computed tomography for I-125 prostate brachytherapy: Impact on seed identification
- 1 November 2016
- Published by Elsevier in Brachytherapy
- Vol. 15 (6) , 768-773
Single-energy metal artifact reduction in postimplant computed tomography for I-125 prostate brachytherapy: Impact on seed identification
- 20 May 2016
- p. 514-9
[Management of morbidity with radiotherapy for prostate cancer].
- 1 December 2014
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 90 (5) , 1069-1075
A Dose–Response Analysis of Biochemical Control Outcomes After 125I Monotherapy for Patients With Favorable-Risk Prostate Cancer
- 1 December 2014
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 90 (5) , 1069-1075
A Dose–Response Analysis of Biochemical Control Outcomes After 125I Monotherapy for Patients With Favorable-Risk Prostate Cancer
- Open Access
- 9 January 2014
- Published by Springer Nature in Radiation Oncology
- Vol. 9 (1) , 13
Combined brachytherapy and external beam radiotherapy without adjuvant androgen deprivation therapy for high-risk prostate cancer
- 9 January 2014
- Published by Springer Nature in Radiation Oncology
- Vol. 9 (1) , 13
Open AccessCombined brachytherapy and external beam radiotherapy without adjuvant androgen deprivation therapy for high-risk prostate cancer
- 1 September 2013
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 87 (1) , 182-187
Novel Parameter Predicting Grade 2 Rectal Bleeding After Iodine-125 Prostate Brachytherapy Combined With External Beam Radiation Therapy
- 1 September 2013
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 87 (1) , 182-187
Novel Parameter Predicting Grade 2 Rectal Bleeding After Iodine-125 Prostate Brachytherapy Combined With External Beam Radiation Therapy